Since NUT has been demonstrated to target many types of hematological malignancies, as well as solid tumors (i.e., breast cancer, retinoblastoma, prostate cancer, lymphoma, and melanoma), this preliminary study suggests that T-ETO may represent a promising delivery system for NUT, possibly able to protect the skin from UV damage. This evidence concerns the gene RUNX1T1 and prostate cancer.